DE60307483D1 - Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen - Google Patents

Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen

Info

Publication number
DE60307483D1
DE60307483D1 DE60307483T DE60307483T DE60307483D1 DE 60307483 D1 DE60307483 D1 DE 60307483D1 DE 60307483 T DE60307483 T DE 60307483T DE 60307483 T DE60307483 T DE 60307483T DE 60307483 D1 DE60307483 D1 DE 60307483D1
Authority
DE
Germany
Prior art keywords
treatment
compounds
formula
employed
alterosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60307483T
Other languages
English (en)
Other versions
DE60307483T2 (de
Inventor
Kenna Jeffrey Mc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Publication of DE60307483D1 publication Critical patent/DE60307483D1/de
Application granted granted Critical
Publication of DE60307483T2 publication Critical patent/DE60307483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
DE60307483T 2002-08-07 2003-08-06 Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen Expired - Lifetime DE60307483T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40169302P 2002-08-07 2002-08-07
US401693P 2002-08-07
PCT/EP2003/008720 WO2004014914A1 (en) 2002-08-07 2003-08-06 Organic compounds as agents for the treatment of aldosterone mediated conditions

Publications (2)

Publication Number Publication Date
DE60307483D1 true DE60307483D1 (de) 2006-09-21
DE60307483T2 DE60307483T2 (de) 2007-07-05

Family

ID=31715720

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307483T Expired - Lifetime DE60307483T2 (de) 2002-08-07 2003-08-06 Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen

Country Status (15)

Country Link
US (1) US7732603B2 (de)
EP (1) EP1537114B8 (de)
JP (1) JP4533139B2 (de)
CN (1) CN100404535C (de)
AT (1) ATE335744T1 (de)
AU (1) AU2003253387A1 (de)
BR (1) BR0313293A (de)
CA (1) CA2494636A1 (de)
CY (1) CY1106217T1 (de)
DE (1) DE60307483T2 (de)
DK (1) DK1537114T3 (de)
ES (1) ES2270143T3 (de)
HK (1) HK1080290A1 (de)
PT (1) PT1537114E (de)
WO (1) WO2004014914A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261225A1 (de) * 2004-05-28 2010-12-15 Novartis AG Heterocyclische Verbindungen und deren Verwendung als Aldosteronsynthaseinhibitoren
TW200611897A (en) * 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EP1842543A1 (de) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmazeutishe Zusammensetzung enthaltend einen Aldosteron-Synthase-Inhibitor und einen Mineralkorticoidrezeptor-Antagonist
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) * 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
EP2029604A2 (de) * 2006-05-26 2009-03-04 Novartis AG Aldosteron-synthase- und/oder 11beta-hydroxylase-hemmer
JP2010501573A (ja) * 2006-08-25 2010-01-21 ノバルティス アクチエンゲゼルシャフト アルドステロン合成酵素および／または１１−β−ヒドロキシラーゼおよび／またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体
MX2009006553A (es) * 2006-12-22 2009-06-26 Actelion Pharmaceuticals Ltd Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina.
JP5485148B2 (ja) * 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
JP2011525910A (ja) * 2008-06-25 2011-09-29 アクテリオン ファーマシューティカルズ リミテッド ５，６，７，８−テトラヒドロ−イミダゾ［１，５−ａ］ピラジン化合物
AR076706A1 (es) 2009-05-28 2011-06-29 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de neprilisina
KR101442897B1 (ko) 2009-05-28 2014-09-23 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
PL2552920T3 (pl) 2010-04-02 2017-08-31 Ogeda Sa Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
RU2609200C2 (ru) 2011-07-08 2017-01-30 Новартис Аг Способ лечения атеросклероза у субъектов с высоким уровнем триглицеридов
ES2572604T3 (es) 2011-10-03 2016-06-01 Euroscreen S.A. Nuevas N-acil-5,6,7,(8-sustituido)-tetrahidro-[1,2,4]–triazolo[4,3–a]pirazinas quirales, como antagonistas selectivas del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por el receptor de NK-3
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MX367525B (es) 2013-02-14 2019-08-26 Novartis Ag Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep).
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
EP3197876B1 (de) 2014-09-25 2018-11-28 Ogeda Sa Neuartige chirale synthese von n-acyl-(3-substituierten)-(8-substituierten)-5,6-dihydro-[1,2,4]triazol[4,3-a]pyrazinen
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
BR112020019824A2 (pt) 2018-03-29 2021-01-05 Board Of Regents, The University Of Texas System Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente
WO2019195846A1 (en) * 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20220024981A1 (en) 2018-11-27 2022-01-27 Novartis Ag Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders
CN113166101A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582315A (en) * 1968-03-22 1971-06-01 Lilly Co Eli Methods and compositions for inhibiting plant growth
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5529992A (en) 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6150347A (en) 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
JPH07101959A (ja) * 1993-09-30 1995-04-18 Sankyo Co Ltd １−メチルカルバペネム誘導体
DE4341453A1 (de) * 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
ATE335744T1 (de) 2006-09-15
EP1537114B1 (de) 2006-08-09
CN100404535C (zh) 2008-07-23
ES2270143T3 (es) 2007-04-01
AU2003253387A1 (en) 2004-02-25
DK1537114T3 (da) 2006-11-13
JP2006505520A (ja) 2006-02-16
US20060166973A1 (en) 2006-07-27
PT1537114E (pt) 2006-12-29
CA2494636A1 (en) 2004-02-19
BR0313293A (pt) 2005-06-14
HK1080290A1 (en) 2006-04-21
EP1537114B8 (de) 2007-10-03
CY1106217T1 (el) 2011-06-08
DE60307483T2 (de) 2007-07-05
JP4533139B2 (ja) 2010-09-01
CN1688583A (zh) 2005-10-26
EP1537114A1 (de) 2005-06-08
WO2004014914A1 (en) 2004-02-19
US7732603B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
DE60307483D1 (de) Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
DE60321593D1 (de) Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
MX2009006631A (es) Imidazoles como inhibidores de sintasa de aldosterona.
WO2007117982A3 (en) Organic compounds
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
UA84453C2 (ru) Применение производных метиленамида для лечения сердечно-сосудистых заболеваний
DE60011430D1 (de) Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
ME01530B (me) Polimorfni oblici 3- (4-amino-1- okso-1, 3-dihidro- izoindol -2-il)-piperidin-2,6- diona
DE60315355D1 (de) Piperidinyl-thiazol-carbonsäure-derivate als angiogenesis inhibitoren
MXPA06014799A (es) Heterociclos de seis miembros utiles como inhibidores de serina proteasa.
WO2009073497A3 (en) Prolyl hydroxylase inhibitors
WO2009079412A3 (en) Reverse transcriptase inhibitors
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
WO2008036216A8 (en) Piperidine derivatives as renin inhibitors
TW200745074A (en) New pharmaceutical compounds
NO20060247L (no) Substituerte spirobenzazepiner
WO2005118554A3 (en) Factor viia inhibitor
WO2005121102A3 (en) Factor viia inhibitor
TW200736264A (en) Thiazolo[4,5-C]pyridine derivatives
DE60302344D1 (de) 1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
DE60330373D1 (de) Piperidinderivate als ccr5-inhibitoren
DE60304047D1 (de) 1-oxa-3-aza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
DE602004021145D1 (de) NEUE SUBSTITUIERTE THIOPHENPYRIMIDINONDERIVATE ALS INHIBITOREN VON 17ß-HYDROXYSTEROIDDEHYDROGENASE
TW200612952A (en) Six-membered heterocycles useful as serine protease inhibitors

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN